MADRID, 30 (EUROPA PRESS)
The results of phase III study Emilia that assessed the treatment of therapy single Roche trastuzumab emtansina in patients of cancer of breast HER2-positive metastatic revealed that those affected saw how their survival increased without worsening their symptoms.
Is a conjugate antibody which first vezcombina in a single molecule by two drugs: trastuzumab (already authorized as a treatment standard for cancer of breast HER2-positive metastatic and marketed as ' Herceptin ') more powerful chemotherapy DM1.
“We are delighted with the results of the study Emilia, trastuzumab emtansina is our first conjugate anticuerpo-fármaco and it could benefit people who need more aggressive disease treatment options,” said the director of international development for Roche, Hal Barron.
In research involving patients with cancer of breast HER2-positive metastatic who had previously received treatment with ' Herceptin ' and with a taxane – chemotherapy – and in comparing trastuzumab emtansina monotherapy with combination of lapatinib and Capecitabine in 991 people with cancer breast HER2-positive metastatic whose disease had progressed following initial treatment.
This, the result revealed that the patients who received trastuzumab emtansina “significantly” lived longer without firsthand worsen their symptoms than the treated with lapatinib and Capecitabine.
Trastuzumab emtansina is an investigational drug, which belongs to the Group of conjugated anticuerpo-fármaco, and which is designed to inhibit the HER2 signaling pathway and bring the chemotherapy agent directly to the interior of HER2-positive cancer cells.
After the results, Roche is planning to request this year to the European Agency of medicines, (EMA, by its acronym in English), the marketing authorisation of trastuzumab emtansina cancer of breast HER2-positive metastatic.
